10-Q: Amgen Reports Q1 2025 Results: Revenue Up 9% Driven by Volume Growth

Amgen's Q1 2025 results show a 9% increase in total revenue, driven primarily by volume growth in key products.

Summary

• Amgen's total revenues for Q1 2025 increased by 9% to $8.149 billion, compared to $7.447 billion in Q1 2024.
• Product sales increased by 11% driven by volume growth of 14%, partially offset by a 6% decline in net selling price.
• U.S. product sales increased by 14%, while ROW (rest of world) product sales increased by 3%.
• Key products driving growth include Prolia (up 10%), Repatha (up 27%), EVENITY (up 29%), Otezla (up 11%), BLINCYTO (up 52%), and TEZSPIRE (up 65%).
• ENBREL sales decreased by 10% due to lower net selling price.
• Operating expenses increased by 8% due to an $800 million Otezla intangible asset impairment charge.
• Net income for Q1 2025 was $1.730 billion, compared to a net loss of $113 million in Q1 2024.
• Diluted earnings per share (EPS) was $3.20, compared to a diluted loss per share of $0.21 in the prior year period.
• The effective tax rate for Q1 2025 was 12.3%, compared to (66.2)% for Q1 2024, primarily due to changes in earnings mix related to equity investments.
• Amgen did not repurchase any shares during Q1 2025, with $6.8 billion remaining authorized for repurchases.
• Debt repayments totaled $2.5 billion during the quarter.
• The company expects volume growth from certain brands to be partially offset by net selling price declines for the remainder of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there are challenges related to pricing pressures and biosimilar competition, the company reported strong revenue growth and a return to profitability. The Otezla impairment charge is a concern, but overall the results are encouraging.

Positives

• Significant revenue growth driven by volume increases in key products.
• Strong performance from Prolia, Repatha, EVENITY, BLINCYTO and TEZSPIRE.
• Return to profitability with a net income of $1.730 billion.
• Successful debt repayments of $2.5 billion.
• FDA approval of UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
• Global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA as a treatment for patients with small cell lung cancer (SCLC) met its primary endpoint at a planned interim analysis.

Negatives

• ENBREL sales decreased by 10% due to lower net selling price.
• KYPROLIS sales decreased by 14% due to increased competition.
• Otezla intangible asset impairment charge of $800 million due to Medicare price setting.
• Overall decline in net selling prices by 6%.

Risks

• Biosimilar competition for Prolia and XGEVA is expected to erode sales in 2025.
• Uncertain macroeconomic conditions and geopolitical conflicts could introduce variability into product sales.
• The IRA's Medicare price setting and redesign are likely to have a material adverse effect on sales.
• Potential for additional tax liabilities from ongoing IRS tax dispute and enactment of the OECD minimum corporate tax rate agreement.
• Cyberattacks and information security breaches could compromise systems and data.
• Reliance on third-party service providers increases cybersecurity risks.
• Potential for safety problems or signals to arise as products are used in clinical practice.
• Global economic conditions may negatively affect the company and magnify certain risks.

Future Outlook

For the remainder of 2025, Amgen expects volume growth from certain brands to be partially offset by net selling price declines. The company intends to continue investing in its business while reducing debt and returning capital to stockholders through dividends and stock repurchases.

Industry Context

Amgen's results reflect the ongoing trends in the biotechnology industry, including increasing competition from biosimilars and generics, pricing pressures from payers, and the impact of government regulations such as the IRA. The company's focus on volume growth and pipeline development is consistent with strategies employed by other large biotechnology companies to navigate these challenges.

Comparison to Industry Standards

• Amgen's revenue growth of 9% is comparable to other large-cap biotechnology companies, such as Johnson & Johnson and AbbVie, which have also reported revenue growth in recent quarters.
• The company's R&D spending as a percentage of revenue (18.2%) is within the typical range for biotechnology companies, reflecting its commitment to innovation.
• The impact of biosimilar competition on ENBREL sales is consistent with the experience of other companies facing biosimilar erosion of their established products.
• The Otezla impairment charge highlights the potential impact of the IRA on pharmaceutical companies' future earnings.
• Amgen's strategic focus on debt reduction and capital return to shareholders is a common practice among mature biotechnology companies.

Legal Proceedings

• Repatha Patent Litigation continues in the Unified Patent Court of the European Union (UPC) and the European Patent Office.
• Prolia/XGEVA BPCIA Litigation continues with a trial scheduled for May 4, 2026, in Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al.
• A confidential settlement was reached in Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al.
• The U.S. Court of Appeals for the Federal Circuit affirmed the denial of Regenerons motion for a preliminary injunction in PAVBLU Patent Litigation.
• Onyx Therapeutics, Inc. filed a lawsuit against Somerset Therapeutics, LLC in KYPROLIS ANDA Patent Litigation.
• Trial is scheduled to begin on May 5, 2025, in Regeneron Pharmaceuticals, Inc. Antitrust Action.
• Sandoz Inc. filed a complaint against Amgen Inc., Amgen Manufacturing Limited LLC, and Immunex Corporation in Sandoz Inc. Antitrust Action.
• U.S. Tax Litigation and Related Matters continue with the trial concluded and post-trial briefs to be filed.
• Securities Class Action Litigation (Roofers Local No. 149 Pension Fund) continues with summary judgment motions due August 12, 2026.
• A shareholder derivative action (Sieveking) was filed on April 2, 2025.
• ChemoCentryx, Inc. Securities Matters continue with the lead plaintiffs summary judgment motion due May 8, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to increased profitability and continued commitment to dividends and stock repurchases.
• Employees: Potential impact from cost containment measures and restructuring efforts.
• Customers (Patients): Potential impact from changes in drug pricing and access due to government regulations and payer actions.
• Suppliers: Potential impact from changes in supply chain costs and tariffs.
• Creditors: Positive impact from debt repayments and improved financial position.

Next Steps

• Continue to advance pipeline programs and seek regulatory approvals.
• Manage the impact of biosimilar competition on key products.
• Address pricing pressures and navigate the implementation of the IRA.
• Monitor and mitigate cybersecurity risks.
• File post-trial briefs and make closing arguments in the U.S. Tax Court case in 2025.

Key Dates

Keywords

Amgen, financial results, Q1 2025, revenue, earnings, product sales, Prolia, Repatha, ENBREL, Otezla, TEZSPIRE, biosimilars, Medicare, IRA, cybersecurity, clinical trials